Schizophrenia and schizoaffective disorders are severe mental conditions characterized by hallucinations, delusions, and mood disturbances. The Journal of Clinical Psychiatry offers a deep dive into these disorders, emphasizing their diagnosis, management, and underlying causes. Our expert editors ensure content is both clinically relevant and actionable, aiding psychiatrists in offering effective and compassionate care.
Schizophrenia and Schizoaffective Disorders
Recently published articles about Schizophrenia/Schizoaffective Disorders
Academic Highlights
Dysregulation of Noradrenergic Activity
November 8, 2024
Dysregulation of noradrenergic activity plays a key role in symptom presentation in major depressive disorder, schizophrenia, Alzheimer’s agitation, and PTSD. This article provides an expert panel’s consensus regarding the...
Recent JCP Articles on Schizophrenia/Schizoaffective Disorders
Recent PCC Articles on Schizophrenia/Schizoaffective Disorders
Rounds in the General Hospital
Evaluation and Management of Treatment-Resistant Schizophrenia
July 2, 2024
If you have ever been uncertain about how to evaluate patients with a chronic psychotic illness or struggled over how best to manage treatment-resistant schizophrenia, then this case vignette...
Narrative Review
Alternative Treatment for Agitation in Schizophrenia and Bipolar Disorder
January 30, 2024
While oral and intramuscular formulations of pharmacologic agents continue to be commonly used to treat acute agitation, novel agents with alternative routes of delivery are becoming available.
The latest news on Schizophrenia/Schizoaffective Disorders
Featured Schizophrenia/Schizoaffective Disorders Research
Letter to the Editor
Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?
March 20, 2024
As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...
Original Research
Safety and Tolerability of Initiating With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months
February 28, 2024
In this post hoc analysis, treatment of acutely exacerbated schizophrenia with aripiprazole lauroxil or paliperidone palmitate was well tolerated, consistent with the safety profiles of these medications.